Cargando…

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease

INTRODUCTION: Progressive language impairment is among the primary components of cognitive decline in Alzheimer's disease (AD). Because expressive and receptive language help to maintain emotional connections to caregivers and support the management of AD patients' functional needs, langua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferris, Steven H, Schmitt, Frederick A, Saxton, Judith, Richardson, Sharon, Mackell, Joan, Sun, Yijun, Xu, Yikang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226311/ https://www.ncbi.nlm.nih.gov/pubmed/21689411 http://dx.doi.org/10.1186/alzrt84

Ejemplares similares

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
por: Hong, Yun Jeong, et al.
Publicado: (2019)

Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease
por: Nakamura, Kazuhito, et al.
Publicado: (2014)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study
por: Zhan, Yijun, et al.
Publicado: (2022)

A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended-Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed States
por: Gadiko, Chaitanya, et al.
Publicado: (2013)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Amantadine intoxication despite moderate renal dysfunction: A case of combined use with donepezil
por: Okada, Kouji, et al.
Publicado: (2020)

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil
por: Tariot, Pierre N., et al.
Publicado: (2022)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study
por: Mehta, Suyog, et al.
Publicado: (2012)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
por: Lang, Frederick M., et al.
Publicado: (2021)

Designing and analyzing language tests /
por: Carr, Nathan T. (Nathan Thomas), 1966-
Publicado: (2011)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

Durable recovery from amblyopia with donepezil
por: Wu, Carolyn, et al.
Publicado: (2023)

Spin and magnetic moment of $^{23}$Mg
por: Yordanov, D T, et al.
Publicado: (2017)

Searching for Cancer Information on the Internet: Analyzing Natural Language Search Queries
por: Bader, Judith L, et al.
Publicado: (2003)

Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil
por: Ortner, Marion, et al.
Publicado: (2020)

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia
por: Chamnanphon, Monpat, et al.
Publicado: (2020)

Role of Donepezil in Autism: Its Conduciveness in Psychopharmacotherapy
por: Srivastava, Rohit Kant, et al.
Publicado: (2011)

Neuroprotective effects of donepezil against cholinergic depletion
por: Cutuli, Debora, et al.
Publicado: (2013)

Cerebellar Cognitive Affective Syndrome Improved by Donepezil
por: Nishida, Yoichiro, et al.
Publicado: (2018)

Donepezil for mild cognitive impairment in Parkinson’s disease
por: Baik, Kyoungwon, et al.
Publicado: (2021)

Suspected donepezil toxicity: A case report
por: Gust, Carmen, et al.
Publicado: (2020)

Effects of Donepezil on the Musculoskeletal System in Female Rats
por: Londzin, Piotr, et al.
Publicado: (2023)

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
por: Schaars, CF, et al.
Publicado: (2006)

Combined Donepezil and Ethanolic Extract of Propolis Improved Memory Better Than Donepezil and Propolis Monotherapy in Wild Type Drosophila melanogaster
por: Ayikobua, Emmanuel Tiyo, et al.
Publicado: (2018)

A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa(®) Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)
por: Kim, Hee-Jin, et al.
Publicado: (2023)

The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis
por: Killin, Lewis O J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7652duqf8bcf7dippf5johmmk2